Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Alogliptin benzoate and pioglitazone hydrochloride

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Alogliptin benzoate and pioglitazone hydrochloride key facts

Used for
Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$4.73 per tablet (alogliptin benzoate 25 mg · pioglitazone hydrochloride 15 mg; NADAC)
Latest FDA recall
None listed

Sources: FDA label (July 28, 2025); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Alogliptin benzoate and pioglitazone hydrochloride used for?
The FDA-approved label (Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, July 28, 2025) says: “Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and pioglitazone tablets are a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Alogliptin benzoate and pioglitazone hydrochloride?
The “Adverse Reactions” section of the FDA label (Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, July 28, 2025) begins: “The following serious adverse reactions are described below or elsewhere in the prescribing information: Congestive Heart Failure [see Boxed Warning and Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Hypersensitivity Reactions [see Warnings and Precautions (5.3)] Hepatic Effects [see Warnings and Precautions (5.4)] Edema [see Warnings and Precautions (5.5)] Fractures [see Warnings and Precautions (5.6)] Urinary Bladder Tumors [see Warnings …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Alogliptin benzoate and pioglitazone hydrochloride?
The “Drug Interactions” section of the FDA label (Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, July 28, 2025) begins: “Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit the pioglitazone dose to 15 mg daily. (7.2) CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (7.3) Topiramate may decrease pioglitazone concentrations. (7.4) 7.1 Insulin Secretagogues and Insulin Insulin and insulin secretagogues are known to cause hypoglycemia.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Alogliptin benzoate and pioglitazone hydrochloride have a boxed warning?
Yes. The FDA label for Alogliptin and Pioglitazone has a boxed warning (“WARNING: CONGESTIVE HEART FAILURE”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Alogliptin benzoate and pioglitazone hydrochloride?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Alogliptin benzoate and pioglitazone hydrochloride been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Alogliptin benzoate and pioglitazone hydrochloride?
2 companies list prescription products of Alogliptin benzoate and pioglitazone hydrochloride in the FDA NDC Directory, including Padagis Israel Pharmaceuticals Ltd and Takeda Pharmaceuticals America, Inc.

What Alogliptin benzoate and pioglitazone hydrochloride is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and pioglitazone tablets are a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic …

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, film coated, oral), Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd; it covers 4 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Its heading: WARNING: CONGESTIVE HEART FAILURE. Read it on the full label →

2 of 2 FDA labels for this medicine have a boxed warning.

Alogliptin benzoate and pioglitazone hydrochloride boxed warning: what the label says

Quoted from the boxed warning of the FDA-approved label.

WARNING: CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of alogliptin and pioglitazone tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)]. After initiation of alogliptin and pioglitazone tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea and/or edema).

Read more of this section

If congestive heart failure develops while taking alogliptin and pioglitazone tablets, consider discontinuation of alogliptin and pioglitazone tablets or dosage reduction of pioglitazone in alogliptin and pioglitazone tablets [see Warnings and Precautions (5.1)]. Alogliptin and pioglitazone tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1)]. Initiation of alogliptin and pioglitazone tablets in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1)]. WARNING: CONGESTIVE HEART FAILURE See full prescribing information for complete boxed warning Thiazolidinediones, including pioglitazone, which is a component of alogliptin and pioglitazone tablets, cause or exacerbate congestive heart failure in some patients. (5.1) After initiation of alogliptin and pioglitazone tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea and/or edema). If congestive heart failure develops while taking alogliptin and pioglitazone tablets, consider discontinuation of alogliptin and pioglitazone tablets or dosage reduction of pioglitazone in alogliptin and pioglitazone tablets. (5.1) Alogliptin and pioglitazone tablets are not recommended in patients with symptomatic heart failure. (5.1) Initiation of alogliptin and pioglitazone tablets in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. (4, 5.1)

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. Read the full label on DailyMed →

Alogliptin benzoate and pioglitazone hydrochloride side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following serious adverse reactions are described below or elsewhere in the prescribing information: Congestive Heart Failure [see Boxed Warning and Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Hypersensitivity Reactions [see Warnings and Precautions (5.3)] Hepatic Effects [see Warnings and Precautions (5.4)] Edema [see Warnings and Precautions (5.5)] Fractures [see Warnings and Precautions (5.6)] Urinary Bladder Tumors [see Warnings …

Table from the label
Number of Patients (%)
Alogliptin 25 mgPlaceboActive Comparator
N=6447N=3469N=2257
Nasopharyngitis309 (5)152 (4)113 (5)
Upper Respiratory Tract Infection287 (5)121 (4)113 (5)
Headache278 (4)101 (3)121 (5)

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. This is part of the section. Read the full label on DailyMed →

Alogliptin benzoate and pioglitazone hydrochloride drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit the pioglitazone dose to 15 mg daily. (7.2) CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (7.3) Topiramate may decrease pioglitazone concentrations. (7.4) 7.1 Insulin Secretagogues and Insulin Insulin and insulin secretagogues are known to cause hypoglycemia.

Read more of this section

Coadministration of alogliptin and pioglitazone tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower dosages of the insulin secretagogue and insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.8)]. 7.2 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the concentration-time curve [AUC]) and half-life of pioglitazone. Therefore, the maximum recommended dosage of alogliptin and pioglitazone tablets is 25 mg of alogliptin and 15 mg of pioglitazone once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. 7.3 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with alogliptin and pioglitazone tablets, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of alogliptin and pioglitazone tablets (25 mg of alogliptin and 45 mg of pioglitazone) [see Clinical Pharmacology (12.3)]. 7.4 Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate [see Clinical Pharmacology (12.3)]. The clinical relevance of this decrease is unknown; however, when alogliptin and pioglitazone tablets and topiramate are used concomitantly, monitor patients for adequate glycemic control.

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. Read the full label on DailyMed →

Alogliptin benzoate and pioglitazone hydrochloride dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Obtain liver tests prior to initiation. Alogliptin and pioglitazone tablets may be taken with or without food.

Read more of this section

(2.1) Individualize the starting dose of alogliptin and pioglitazone tablets based on the patient’s current regimen and concurrent medical condition but do not exceed a daily dose of alogliptin 25 mg and pioglitazone 45 mg. (2.2) The recommended starting dosage in patients with NYHA Class I or II congestive heart failure is 25 mg of alogliptin and 15 mg of pioglitazone (2.4) Prior to initiation, assess renal function with creatinine clearance (CrCl) (2.3) Mild renal impairment (creatinine clearance [CrCl] ≥60 mL/min): same as the recommended dosage in patients with normal renal function. Moderate renal impairment (CrCl ≥30 to <60 mL/min): 12.5 mg of alogliptin and 30 mg of pioglitazone once daily. Severe renal impairment (CrCl ≥15 to <30 mL/min) or ESRD (CrCl <15 mL/min or requiring hemodialysis): not recommended. 2.1 Important Dosage and Administration Information Obtain liver tests (serum alanine and aspartate aminotransferases, alkaline phosphatase, and total bilirubin) prior to initiating alogliptin and pioglitazone tablets [see Warnings and Precautions (5.4)]. Take alogliptin and pioglitazone tablets orally once daily. Do not split tablets. Alogliptin and pioglitazone tablets may be taken with or without food [see Clinical Pharmacology (12.3)]. If a dose is missed, do not double the next dose. 2.2 Recommended Dosage and Administration Recommended Starting Dosage Based on Current Regimen Individualize the starting dosage of alogliptin and pioglitazone tablets based on the patient's current regimen and the available strengths of alogliptin and pioglitazone tablets (see Table 1). Table 1: Recommended Starting Dosage Based on the Patient’s Current Regimen Current Regimen Starting Dosage of Alogliptin and Pioglitazone Tablets For dosage recommendations for patients with renal impairment and/or congestive heart failure, [see Dosage and Administration (2.3, 2.4)]. Not treated with either alogliptin or pioglitazone 25 mg/15 mg or 25 mg/30 mg Alogliptin 25 mg/15 mg or 25 mg/30 mg Pioglitazone 25 mg/15 mg, 25 mg/30 mg, or 25 mg/45 mg Alogliptin and pioglitazone Select a dosage that is as close as possible to the current dosage of alogliptin and pioglitazone Dosage Titration for Additional Glycemic Control Titrate the alogliptin and pioglitazone tablets dosage gradually, as needed, after assessing therapeutic response and tolerability, up to a maximum dosage of 25 mg of alogliptin and 45 mg of pioglitazone once daily. 2.3 Recommended Dosage for Patients with Renal Impairment Assess renal function prior to initiation of alogliptin and pioglitazone tablets and periodically thereafter [see Use in Specific Populations (8.6)].

Table from the label
Current RegimenStarting Dosage of Alogliptin and Pioglitazone TabletsFor dosage recommendations for patients with renal impairment and/or congestive heart failure, [see Dosage and Administration (2.3, 2.4)].
Not treated with either alogliptin or pioglitazone25 mg/15 mg or 25 mg/30 mg
Alogliptin25 mg/15 mg or 25 mg/30 mg
Pioglitazone25 mg/15 mg, 25 mg/30 mg, or 25 mg/45 mg
Alogliptin and pioglitazoneSelect a dosage that is as close as possible to the current dosage of alogliptin and pioglitazone

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. This is part of the section. Read the full label on DailyMed →

Alogliptin benzoate and pioglitazone hydrochloride in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Limited data with alogliptin and pioglitazone tablets in pregnant women are not sufficient to inform a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations].

Read more of this section

In animal reproduction studies, no adverse developmental effects were observed when pioglitazone was administered to pregnant rats and rabbits during organogenesis at exposures up to 5 and 35 times the 45 mg clinical dose, respectively, based on body surface area. No adverse developmental effects were observed when alogliptin was administered to pregnant rats and rabbits during organogenesis at exposures 180 and 149 times the 25 mg clinical dose, respectively, based on plasma drug exposure (AUC) [see Data]. The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo/Fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity. Data Animal Data Alogliptin and Pioglitazone Co-administration of 100 mg/kg alogliptin and 40 mg/kg pioglitazone (39 and 10 times the 25 mg and 45 mg clinical doses, respectively, based on body surface area) to pregnant rats during organogenesis slightly augmented pioglitazone-related fetal effects of delayed development and reduced fetal weights but did not result in embryofetal mortality or teratogenicity. Alogliptin Alogliptin administered to pregnant rabbits and rats during the period of organogenesis did not cause adverse developmental effects at doses of up to 200 mg/kg and 500 mg/kg, or 149 times and 180 times, the 25 mg clinical dose, respectively, based on plasma drug exposure (AUC). Placental transfer of alogliptin into the fetus was observed following oral dosing to pregnant rats. No adverse developmental outcomes were observed in offspring when alogliptin was administered to pregnant rats during gestation and lactation at doses up to 250 mg/kg (~95 times the 25 mg clinical dose, based on AUC). Pioglitazone Pioglitazone administered to pregnant rats during organogenesis did not cause adverse developmental effects at a dose of 20 mg/kg (~5-times the 45 mg clinical dose), but delayed parturition and reduced embryofetal viability at 40 and 80 mg/kg, or ≥9-times the 45 mg clinical dose, by body surface area.

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. This is part of the section. Read the full label on DailyMed →

When Alogliptin benzoate and pioglitazone hydrochloride should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Alogliptin and pioglitazone tablets are contraindicated in patients with: Established NYHA Class III or IV heart failure at the time of alogliptin and pioglitazone tablets initiation [see Boxed Warning]. A history of serious hypersensitivity reaction to alogliptin, pioglitazone, or any of the excipients in alogliptin and pioglitazone tablets.

Read more of this section

Reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported [see Warnings and Precautions (5.3), Adverse reactions (6.2)]. In patients with established NYHA Class III or IV heart failure at the time of alogliptin and pioglitazone tablets initiation. (4) In patients with a history of serious hypersensitivity reaction to alogliptin, pioglitazone, or any of the excipients in alogliptin and pioglitazone tablets. (4)

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. Read the full label on DailyMed →

Alogliptin benzoate and pioglitazone hydrochloride overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

In the event of an overdose, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract. Alogliptin is minimally dialyzable; over a three-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an overdose situation.

Read more of this section

It is not known if alogliptin is dialyzable by peritoneal dialysis. In the event of an overdose, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.

— FDA label: Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet, film coated
RouteOral
Prescription products8 in the FDA NDC Directory
Brand namesOseni

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Alogliptin benzoate and pioglitazone hydrochloride, by strength and form
Strength and formGeneric or brandPharmacies pay
alogliptin benzoate 25 mg · pioglitazone hydrochloride 15 mg
tablet, film coated
Generic $4.73 per tablet

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA022426
OSENI
Takeda Pharms USAJanuary 25, 2013 10, latest June 28, 2024
2024: Labeling · 2022: Labeling · 2019: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)1368410, 1368416, 1368424, 1368430, 1368431, 1368437, 1368438, 1368444
SPL set ID of the quoted label642b1e90-701e-42f2-bac6-a4918738e2c9
FDA labels (SPL)2
FDA applicationsNDA022426
Active ingredients (FDA)ALOGLIPTIN BENZOATE / PIOGLITAZONE HYDROCHLORIDE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Alogliptin and Pioglitazone, Padagis Israel Pharmaceuticals Ltd, effective July 28, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers